Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;35(3):101492.
doi: 10.1016/j.beem.2021.101492. Epub 2021 Feb 10.

Gut microbiota and their metabolites in cardiovascular disease

Affiliations
Free article
Review

Gut microbiota and their metabolites in cardiovascular disease

Valérie Lbi Jansen et al. Best Pract Res Clin Endocrinol Metab. 2021 May.
Free article

Abstract

The gut microbiome affects the development and progress of various types of disease such as obesity, diabetes, atherosclerosis and arterial thrombosis. Gut microbiome derived metabolites have been established to be predictive of arterial thrombosis in epidemiological studies. In these studies atherosclerosis and prothrombotic effect cannot be distinguished but preclinical studies show gut derived metabolites can induce platelet hyperreactivity and increase thrombotic potential. Gut commensals can also influence platelets through serotonin synthesis and may enhance Von Willebrand factor production. The effects on secondary haemostasis are less studied. In antiphospholipid syndrome, a thrombotic auto-immune disorder, autoreactive T cells and antibodies cross-react with auto-antigen mimicking peptides from gut commensals which appears to contribute to the pathophysiology. This review focusses on the prothrombotic effect of the gut microbiome and aims to provide insight into its influence on thromboembolic disease and the haemostatic system.

Keywords: dysbiosis; gastrointestinal microbiome; haemostasis; stroke; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest S.M. reports grants and personal fees from Bayer, BMS Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Portola, GSK and Aspen and personal fees from Sanofi. The other authors declare no potential conflict of interest.

LinkOut - more resources